Mirati wins over a Chinese partner for KRAS hopeful, looking to tail Amgen’s breakthrough win

In a gunshot heard across oncology, the FDA handed Amgen a breakthrough win for a first-of-its-kind KRAS inhibitor — once considered “undruggable” — late last week. The drug’s biggest competitor, not content to rest on its laurels, has now signed a major marketing deal in China as it eyes...

Click to view original post